Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP HFpEF DM: Semaglutide 2.4 mg in obesity-related HFpEF with type 2 diabetes (Japan)
jRCT2061210014Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Trial of semaglutide in heart failure with preserved ejection fraction (HFpEF), obesity and type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoints: Change in KCCQ clinical summary score from baseline to week 52 and Change in body weight (%) from baseline to week 52. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2061210014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210014.